News Releases
View printer-friendly version < < backNEW BRUNSWICK, N.J., Oct 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.
Net earnings and diluted earnings per share for the third quarter of 2009 were $3.3 billion and $1.20, respectively, representing increases of 1.1% and 2.6%, as compared to the same period in 2008. The Company raised its earnings guidance for full-year 2009 to $4.54 - $4.59 per share, which excludes the impact of special items.
"We continue to successfully manage our broad base of businesses and deliver solid earnings despite the impact of patent expirations and the challenges posed by the current economic environment," said William C. Weldon, Chairman and Chief Executive Officer. "We completed multiple acquisitions and strategic collaborations and received several new product approvals in the quarter that will benefit patients worldwide and drive future growth."
Worldwide Consumer sales of $4.0 billion for the third quarter represented a decrease of 2.7% versus the prior year with an increase of 1.1% operationally and a negative impact from currency of 3.8%. Domestic sales decreased 4.4%; international sales decreased 1.4%, which reflected an operational increase of 5.2% and a negative currency impact of 6.6%.
Contributing to operational sales growth during the quarter were sales of Dabao skin care products; AVEENO® skin care products; SPLENDA® No Calorie Sweetener; Le Petit Marseillais® beauty care products; and LISTERINE® antiseptic mouthrinse. Other growth drivers were sales from the acquisition of Vania Expansion SNC.
Worldwide Pharmaceutical sales of $5.3 billion for the third quarter represented a decrease of 14.1% versus the prior year with an operational decline of 11.9% and a negative impact from currency of 2.2%. Domestic sales decreased 19.2%; international sales decreased 7.1%, which reflected an operational decrease of 1.9% and a negative currency impact of 5.2%.
REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases, demonstrated solid sales performance during the quarter. Several other pharmaceutical products had strong growth including PREZISTA® (darunavir), a treatment for HIV; VELCADE® (bortezomib), a treatment for multiple myeloma; and RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment, an antipsychotic medication. Sales results of TOPAMAX® (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL® (risperidone), an antipsychotic medication, were negatively impacted by generic competition.
During the quarter, the U.S. Food and Drug Administration (FDA) approved STELARA( ) (ustekinumab) for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA also approved INVEGA® SUSTENNA (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults; the first once-monthly, long-acting, injectable atypical antipsychotic approved in the U.S. for this use. In addition, the FDA approved the Supplemental New Drug Application for INVEGA® (paliperidone) extended-release tablets for the acute treatment of schizoaffective disorder either as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants.
On Oct. 6, the European Commission approved SIMPONI (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis, active and progressive psoriatic arthritis and severe, active ankylosing spondylitis.
During the quarter, the Company completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program as well as an equity investment in Elan. Additionally, the Company announced that it had entered into a licensing and collaboration agreement with Gilead Sciences, Inc., for the development and commercialization of a new fixed dose combination of investigational compound TMC278 (rilpivirine hydrochloride 25 mg) and Gilead's TRUVADA® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for treatment-naive adult patients with HIV-1.
Early in the fourth quarter, the Company announced that it had entered into a strategic collaboration with Crucell, N.V., focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases. The agreement also included an 18% equity investment in Crucell, N.V.
Worldwide Medical Devices and Diagnostics sales of $5.8 billion for the third quarter represented an increase of 2.3% versus the prior year with an operational increase of 4.1% and a negative currency impact of 1.8%. Domestic sales increased 4.5%; international sales increased 0.5%, which reflected an operational increase of 3.8% and a negative currency impact of 3.3%.
Primary contributors to the operational growth included Ethicon's surgical care and aesthetics products; Ethicon Endo-Surgery's minimally invasive products; DePuy's orthopaedic joint reconstruction, spine, and sports medicine businesses; and Ortho-Clinical Diagnostics' professional products. This growth was partially offset by lower sales in the Cordis franchise, reflecting strong competition in the drug-eluting stent market, and the 2008 divestiture of the Professional Wound Care products in our Ethicon business.
About Johnson & Johnson
Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 117,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
NOTE TO INVESTORS
Johnson & Johnson will conduct a meeting with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. The schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson can be found on the Company's website at www.jnj.com.
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited; Dollars in Millions) THIRD QUARTER
-------------------------------- -------------
Percent Change
--------------
2009 2008 Total Operations Currency
--------------------- ---- ---- ----- ---------- --------
Sales to customers by
segment of business
Consumer
U.S. $1,691 1,769 (4.4)% (4.4) -
International 2,298 2,330 (1.4) 5.2 (6.6)
----------------- ----- ----- ---- --- ----
3,989 4,099 (2.7) 1.1 (3.8)
----- ----- ---- --- ----
Pharmaceutical
U.S. 2,857 3,538 (19.2) (19.2) -
International 2,392 2,575 (7.1) (1.9) (5.2)
----------------- ----- ----- ---- ---- ----
5,249 6,113 (14.1) (11.9) (2.2)
----- ----- ----- ----- ----
Med Devices & Diagnostics
U.S. 2,766 2,648 4.5 4.5 -
International 3,077 3,061 0.5 3.8 (3.3)
----------------- ----- ----- --- --- ----
5,843 5,709 2.3 4.1 (1.8)
----- ----- --- --- ----
U.S. 7,314 7,955 (8.1) (8.1) -
International 7,767 7,966 (2.5) 2.4 (4.9)
------------- ----- ----- ---- --- ----
Worldwide $15,081 15,921 (5.3)% (2.8) (2.5)
--------- ------- ------ ---- ---- ----
(Unaudited; Dollars in Millions) NINE MONTHS
-------------------------------- -----------
Percent Change
--------------
2009 2008 Total Operations Currency
--------------------- ---- ---- ----- ---------- --------
Sales to customers by
segment of business
Consumer
U.S. $5,125 5,282 (3.0)% (3.0) -
International 6,429 6,917 (7.1) 4.1 (11.2)
----------------- ----- ----- ---- --- -----
11,554 12,199 (5.3) 1.0 (6.3)
------ ------ ---- --- ----
Pharmaceutical
U.S. 9,703 11,401 (14.9) (14.9) -
International 6,824 7,481 (8.8) 1.4 (10.2)
----------------- ----- ----- ---- --- -----
16,527 18,882 (12.5) (8.5) (4.0)
------ ------ ----- ---- ----
Med Devices & Diagnostics
U.S. 8,194 7,959 3.0 3.0 -
International 9,071 9,525 (4.8) 3.7 (8.5)
----------------- ----- ----- ---- --- ----
17,265 17,484 (1.3) 3.3 (4.6)
------ ------ ---- --- ----
U.S. 23,022 24,642 (6.6) (6.6) -
International 22,324 23,923 (6.7) 3.1 (9.8)
------------- ------ ------ ---- --- ----
Worldwide $45,346 48,565 (6.6)% (1.8) (4.8)
--------- ------- ------ ---- ---- ----
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited; Dollars in Millions) THIRD QUARTER
-------------------------------- -------------
Percent Change
--------------
2009 2008 Total Operations Currency
--------------------- ---- ---- ----- ---------- --------
Sales to customers by
geographic area
U.S. $7,314 7,955 (8.1)% (8.1) -
---- ------ ----- ---- ---- --
Europe 3,879 4,076 (4.8) 2.1 (6.9)
Western Hemisphere
excluding U.S. 1,338 1,461 (8.4) 1.5 (9.9)
Asia-Pacific, Africa 2,550 2,429 5.0 3.5 1.5
-------------------- ----- ----- --- --- ---
International 7,767 7,966 (2.5) 2.4 (4.9)
------------- ----- ----- ---- --- ----
Worldwide $15,081 15,921 (5.3)% (2.8) (2.5)
--------- ------- ------ ---- ---- ----
(Unaudited; Dollars in Millions) NINE MONTHS
-------------------------------- -----------
Percent Change
--------------
2009 2008 Total Operations Currency
--------------------- ---- ---- ----- ---------- --------
Sales to customers by
geographic area
U.S. $23,022 24,642 (6.6)% (6.6) -
---- ------- ------ ---- ---- --
Europe 11,522 12,931 (10.9) 1.2 (12.1)
Western Hemisphere
excluding U.S. 3,615 3,986 (9.3) 5.8 (15.1)
Asia-Pacific, Africa 7,187 7,006 2.6 5.1 (2.5)
-------------------- ----- ----- --- --- ----
International 22,324 23,923 (6.7) 3.1 (9.8)
------------- ------ ------ ---- --- ----
Worldwide $45,346 48,565 (6.6)% (1.8) (4.8)
--------- ------- ------ ---- ---- ----
Johnson & Johnson and Subsidiaries
----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except
Per Share Figures) THIRD QUARTER
------------------ -------------
2009 2008
---------------- ---------------- Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
------------------ ------ -------- ------ -------- ---------
Sales to customers $15,081 100.0 $15,921 100.0 (5.3)
------------------ ------- ----- ------- ----- ----
Cost of products sold 4,434 29.4 4,774 30.0 (7.1)
Selling, marketing
and administrative
expenses 4,767 31.6 5,195 32.6 (8.2)
Research expense 1,617 10.7 1,861 11.7 (13.1)
Interest (income)
expense, net 114 0.7 25 0.2
Other (income)
expense, net (96) (0.6) (224) (1.4)
--------------------- --- ---- ---- ---- ----
Earnings before
provision for taxes
on income 4,245 28.2 4,290 26.9 (1.0)
Provision for taxes
on income 900 6.0 980 6.1 (8.2)
------------------- --- --- --- --- ----
Net earnings $3,345 22.2 $3,310 20.8 1.1
------------ ------ ---- ------ ---- ---
Net earnings per
share (Diluted) $1.20 $1.17 2.6
Average shares
outstanding (Diluted) 2,793.0 2,831.3
Effective tax rate 21.2% 22.8%
Johnson & Johnson and Subsidiaries
----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except
Per Share Figures) NINE MONTHS
------------------ -----------
2009 2008
---------------- -------------------- Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
---------- ------ -------- ------ -------- ------------
Sales to
customers $45,346 100.0 $48,565 100.0 (6.6)
---------- ------- ----- ------- ----- ----
Cost of products
sold 13,135 29.0 14,139 29.1 (7.1)
Selling, marketing
and administrative
expenses 14,172 31.3 15,825 32.6 (10.4)
Research expense 4,773 10.5 5,469 11.3 (12.7)
In-process research
& development - - 40 0.1
Interest (income)
expense, net 280 0.6 57 0.1
Other (income)
expense, net (165) (0.4) (377) (0.8)
----------------- ---- ---- ---- ---- ----
Earnings before
provision for
taxes on income 13,151 29.0 13,412 27.6 (1.9)
Provision for
taxes on income 3,091 6.8 3,177 6.5 (2.7)
---------------- ----- --- ----- --- ----
Net earnings $10,060 22.2 $10,235 21.1 (1.7)
------------ ------- ---- ------- ---- ----
Net earnings per
share (Diluted) $3.61 $3.60 0.3
Average shares
outstanding
(Diluted) 2,787.9 2,847.8
Effective tax rate 23.5% 23.7%
-----------------
Adjusted earnings
before provision
for taxes and
net earnings
Earnings before
provision for
taxes on
income $13,151 29.0 $13,452 (1) 27.7 (2.2)
Net earnings $10,060 22.2 $10,275 (1) 21.2 (2.1)
Net earnings
per share
(Diluted) $3.61 $3.61 (1) 0.0
Effective tax
rate 23.5% 23.6%
---- ---- ---- ---
(1) The difference between as reported earnings and as adjusted earnings
before provision for taxes on income and net earnings and net earnings
per share (diluted) is IPR&D of $40 million with no tax benefit and
$0.01 per share, respectively.
REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER
-------------
% Change
-----------------------------------
2009 2008 Reported Operational (1) Currency
---- ---- -------- --------------- --------
CONSUMER SEGMENT (2)
---------------------
SKIN CARE
---------
US 370 358 3.4% 3.4% -
Intl 472 500 -5.6% -0.1% -5.5%
WW 842 858 -1.9% 1.3% -3.2%
BABY CARE
---------
US 102 114 -10.5% -10.5% -
Intl 442 472 -6.4% -0.7% -5.7%
WW 544 586 -7.2% -2.6% -4.6%
ORAL CARE
---------
US 187 204 -8.3% -8.3% -
Intl 223 230 -3.0% 4.8% -7.8%
WW 410 434 -5.5% -1.4% -4.1%
OTC/NUTRITIONALS
----------------
US 732 778 -5.9% -5.9% -
Intl 666 661 0.8% 8.0% -7.2%
WW 1,398 1,439 -2.8% 0.5% -3.3%
WOMEN'S HEALTH
--------------
US 142 164 -13.4% -13.4% -
Intl 360 346 4.0% 11.7% -7.7%
WW 502 510 -1.6% 3.6% -5.2%
WOUND CARE / OTHER
------------------
US 158 151 4.6% 4.6% -
Intl 135 121 11.6% 18.0% -6.4%
WW 293 272 7.7% 10.5% -2.8%
TOTAL CONSUMER
--------------
US 1,691 1,769 -4.4% -4.4% -
Intl 2,298 2,330 -1.4% 5.2% -6.6%
WW 3,989 4,099 -2.7% 1.1% -3.8%
NINE MONTHS
-----------
% Change
-----------------------------------
2009 2008 Reported Operational (1) Currency
---- ---- -------- --------------- --------
CONSUMER SEGMENT (2)
---------------------
SKIN CARE
---------
US 1,204 1,119 7.6% 7.6% -
Intl 1,313 1,418 -7.4% 3.0% -10.4%
WW 2,517 2,537 -0.8% 5.0% -5.8%
BABY CARE
---------
US 308 340 -9.4% -9.4% -
Intl 1,233 1,351 -8.7% 0.7% -9.4%
WW 1,541 1,691 -8.9% -1.4% -7.5%
ORAL CARE
---------
US 549 588 -6.6% -6.6% -
Intl 612 640 -4.4% 8.3% -12.7%
WW 1,161 1,228 -5.5% 1.1% -6.6%
OTC/NUTRITIONALS
----------------
US 2,137 2,299 -7.0% -7.0% -
Intl 1,919 2,139 -10.3% 1.8% -12.1%
WW 4,056 4,438 -8.6% -2.8% -5.8%
WOMEN'S HEALTH
--------------
US 443 470 -5.7% -5.7% -
Intl 963 1,005 -4.2% 7.2% -11.4%
WW 1,406 1,475 -4.7% 3.1% -7.8%
WOUND CARE / OTHER
------------------
US 484 466 3.9% 3.9% -
Intl 389 364 6.9% 18.8% -11.9%
WW 873 830 5.2% 10.5% -5.3%
TOTAL CONSUMER
--------------
US 5,125 5,282 -3.0% -3.0% -
Intl 6,429 6,917 -7.1% 4.1% -11.2%
WW 11,554 12,199 -5.3% 1.0% -6.3%
* See footnotes below
THIRD QUARTER
-------------
% Change
--------
2009 2008 Reported Operational (1) Currency
---- ---- -------- --------------- --------
PHARMACEUTICAL SEGMENT (2)
---------------------------
ACIPHEX/PARIET
--------------
US 131 130 0.8% 0.8% -
Intl 130 152 -14.5% -9.0% -5.5%
WW 261 282 -7.4% -4.4% -3.0%
CONCERTA
--------
US 205 190 7.9% 7.9% -
Intl 79 208 -62.0% -59.2% -2.8%
WW 284 398 -28.6% -27.2% -1.4%
DURAGESIC/FENTANYL TRANSDERMAL
------------------------------
US 38 54 -29.6% -29.6% -
Intl 168 205 -18.0% -15.2% -2.8%
WW 206 259 -20.5% -18.3% -2.2%
LEVAQUIN/FLOXIN
---------------
US 294 313 -6.1% -6.1% -
Intl 17 20 -15.0% 0.3% -15.3%
WW 311 333 -6.6% -5.7% -0.9%
PROCRIT/EPREX
--------------
US 299 334 -10.5% -10.5% -
Intl 243 285 -14.7% -9.6% -5.1%
WW 542 619 -12.4% -10.0% -2.4%
RAZADYNE/REMINYL
----------------
US 1 31 -96.8% -96.8% -
Intl 96 107 -10.3% -3.8% -6.5%
WW 97 138 -29.7% -24.7% -5.0%
REMICADE
--------
US 822 778 5.7% 5.7% -
US Exports (4) 208 198 5.1% 5.1% -
Intl 6 2 200.0% 198.7% 1.3%
WW 1,036 978 5.9% 5.9% -
RISPERDAL/RISPERIDONE
----------------------
US 35 122 -71.3% -71.3% -
Intl 157 198 -20.7% -21.4% 0.7%
WW 192 320 -40.0% -40.4% 0.4%
RISPERDAL CONSTA
----------------
US 129 118 9.3% 9.3% -
Intl 224 220 1.8% 10.2% -8.4%
WW 353 338 4.4% 9.9% -5.5%
TOPAMAX
-------
US 72 606 -88.1% -88.1% -
Intl 103 122 -15.6% -7.9% -7.7%
WW 175 728 -76.0% -74.7% -1.3%
VELCADE
-------
US - 1 -100.0% -100.0% -
Intl 231 189 22.2% 31.1% -8.9%
WW 231 190 21.6% 30.5% -8.9%
OTHER
-----
US 623 663 -6.0% -6.0% -
Intl 938 867 8.2% 13.6% -5.4%
WW 1,561 1,530 2.0% 5.1% -3.1%
TOTAL PHARMACEUTICAL
--------------------
US 2,857 3,538 -19.2% -19.2% -
Intl 2,392 2,575 -7.1% -1.9% -5.2%
WW 5,249 6,113 -14.1% -11.9% -2.2%
MAJOR NEW PHARM PRODUCTS (5)
----------------------------
PREZISTA
--------
US 78 34 129.4% 129.4% -
Intl 73 45 62.2% 77.0% -14.8%
WW 151 79 91.1% 99.5% -8.4%
INVEGA
------
US 61 73 -16.4% -16.4% -
Intl 36 16 125.0% 142.5% -17.5%
WW 97 89 9.0% 12.3% -3.3%
NINE MONTHS
-----------
% Change
-----------------------------------
2009 2008 Reported Operational (1) Currency
---- ---- -------- --------------- --------
PHARMACEUTICAL SEGMENT (2)
---------------------------
ACIPHEX/PARIET
--------------
US 397 399 -0.5% -0.5% -
Intl 387 485 -20.2% -9.3% -10.9%
WW 784 884 -11.3% -5.3% -6.0%
CONCERTA
--------
US 707 622 13.7% 13.7% -
Intl 238 345 -31.0% -20.8% -10.2%
WW 945 967 -2.3% 1.3% -3.6%
DURAGESIC/FENTANYL TRANSDERMAL
------------------------------
US 163 199 -18.1% -18.1% -
Intl 492 565 -12.9% -4.3% -8.6%
WW 655 764 -14.3% -8.0% -6.3%
LEVAQUIN/FLOXIN
---------------
US 1,045 1,117 -6.4% -6.4% -
Intl 53 63 -15.9% 1.4% -17.3%
WW 1,098 1,180 -6.9% -6.0% -0.9%
PROCRIT/EXPREX
--------------
US 950 1,014 -6.3% -6.3% -
Intl 719 886 -18.8% -9.0% -9.8%
WW 1,669 1,900 -12.2% -7.6% -4.6%
RAZADYNE/REMINYL
----------------
US 30 123 -75.6% -75.6% -
Intl 275 316 -13.0% -1.2% -11.8%
WW 305 439 -30.5% -22.0% -8.5%
REMICADE
--------
US 2,330 2,138 9.0% 9.0% -
US Exports (4) 821 718 14.3% 14.3% -
Intl 15 6 150.0% 145.8% 4.2%
WW 3,166 2,862 10.6% 10.6% -
RISPERDAL/RISPERIDONE
----------------------
US 223 1,196 -81.4% -81.4% -
Intl 483 645 -25.1% -21.3% -3.8%
WW 706 1,841 -61.7% -60.4% -1.3%
RISPERDAL CONSTA
----------------
US 386 339 13.9% 13.9% -
Intl 640 651 -1.7% 12.6% -14.3%
WW 1,026 990 3.6% 13.0% -9.4%
TOPAMAX
-------
US 642 1,674 -61.6% -61.6% -
Intl 317 377 -15.9% -3.5% -12.4%
WW 959 2,051 -53.2% -50.9% -2.3%
VELCADE
-------
US - 4 -100.0% -100.0% -
Intl 652 575 13.4% 26.7% -13.3%
WW 652 579 12.6% 25.8% -13.2%
OTHER
-----
US 2,009 1,858 8.1% 8.1% -
Intl 2,553 2,567 -0.5% 9.2% -9.7%
WW 4,562 4,425 3.1% 8.8% -5.7%
TOTAL PHARMACEUTICAL
--------------------
US 9,703 11,401 -14.9% -14.9% -
Intl 6,824 7,481 -8.8% 1.4% -10.2%
WW 16,527 18,882 -12.5% -8.5% -4.0%
MAJOR NEW PHARM PRODUCTS (5)
----------------------------
PREZISTA
--------
US 215 109 97.2% 97.2% -
Intl 198 132 50.0% 70.0% -20.0%
WW 413 241 71.4% 82.3% -10.9%
INVEGA
------
US 194 192 1.0% 1.0% -
Intl 93 39 138.5% 168.1% -29.6%
WW 287 231 24.2% 29.2% -5.0%
* See footnotes below
THIRD QUARTER
-------------
% Change
-----------------------------------
2009 2008 Reported Operational (1) Currency
---- ---- -------- --------------- --------
MEDICAL DEVICES
AND DIAG (2) (3)
-----------------
CORDIS (6)
----------
US 233 259 -10.0% -10.0% -
Intl 407 431 -5.6% -4.6% -1.0%
WW 640 690 -7.2% -6.6% -0.6%
DEPUY
-----
US 740 698 6.0% 6.0% -
Intl 544 533 2.1% 7.6% -5.5%
WW 1,284 1,231 4.3% 6.7% -2.4%
DIABETES CARE
-------------
US 332 349 -4.9% -4.9% -
Intl 302 318 -5.0% -0.4% -4.6%
WW 634 667 -4.9% -2.7% -2.2%
ETHICON
-------
US 439 372 18.0% 18.0% -
Intl 580 585 -0.9% 3.8% -4.7%
WW 1,019 957 6.5% 9.4% -2.9%
ETHICON ENDO-SURGERY
--------------------
US 499 473 5.5% 5.5% -
Intl 607 569 6.7% 10.9% -4.2%
WW 1,106 1,042 6.1% 8.4% -2.3%
ORTHO-CLINICAL DIAGNOSTICS
--------------------------
US 285 261 9.2% 9.2% -
Intl 216 209 3.3% 7.0% -3.7%
WW 501 470 6.6% 8.2% -1.6%
VISION CARE
-----------
US 238 236 0.8% 0.8% -
Intl 421 416 1.2% -0.2% 1.4%
WW 659 652 1.1% 0.2% 0.9%
TOTAL MEDICAL DEVICES AND DIAG
------------------------------
US 2,766 2,648 4.5% 4.5% -
Intl 3,077 3,061 0.5% 3.8% -3.3%
WW 5,843 5,709 2.3% 4.1% -1.8%
NINE MONTHS
-----------
% Change
-----------------------------------
2009 2008 Reported Operational (1) Currency
---- ---- -------- --------------- --------
MEDICAL DEVICES
AND DIAG (2) (3)
-----------------
CORDIS (6)
----------
US 731 929 -21.3% -21.3% -
Intl 1,251 1,375 -9.0% -3.9% -5.1%
WW 1,982 2,304 -14.0% -10.9% -3.1%
DEPUY
-----
US 2,268 2,129 6.5% 6.5% -
Intl 1,631 1,717 -5.0% 6.8% -11.8%
WW 3,899 3,846 1.4% 6.7% -5.3%
DIABETES CARE
-------------
US 908 990 -8.3% -8.3% -
Intl 877 966 -9.2% 0.2% -9.4%
WW 1,785 1,956 -8.7% -4.1% -4.6%
ETHICON
-------
US 1,296 1,087 19.2% 19.2% -
Intl 1,717 1,835 -6.4% 3.6% -10.0%
WW 3,013 2,922 3.1% 9.3% -6.2%
ETHICON ENDO-SURGERY
--------------------
US 1,442 1,386 4.0% 4.0% -
Intl 1,794 1,783 0.6% 10.6% -10.0%
WW 3,236 3,169 2.1% 7.7% -5.6%
ORTHO-CLINICAL DIAGNOSTICS
--------------------------
US 846 749 13.0% 13.0% -
Intl 616 640 -3.8% 4.8% -8.6%
WW 1,462 1,389 5.3% 9.3% -4.0%
VISION CARE
-----------
US 703 689 2.0% 2.0% -
Intl 1,185 1,209 -2.0% 0.3% -2.3%
WW 1,888 1,898 -0.5% 0.9% -1.4%
TOTAL MEDICAL DEVICES AND DIAG
------------------------------
US 8,194 7,959 3.0% 3.0% -
Intl 9,071 9,525 -4.8% 3.7% -8.5%
WW 17,265 17,484 -1.3% 3.3% -4.6%
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Prior year amounts have been reclassified to conform with current
presentation
(4) For external purposes, reported as U.S. sales
(5) Included in Other
(6) Includes sales of Drug-Eluting Stents for Q3 2009 of $53, $158 and
$211MM Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for Q3 2008 of $97, $192 and
$289MM Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for September YTD 2009 of $189,
$507 and $696MM Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for September YTD 2008 of $433,
$650 and $1,083MM Domestic, International and Worldwide respectively
SOURCE Johnson & Johnson
http://www.jnj.com
Copyright © 2009 PR Newswire. All rights reserved